- NCIt
- C9383
- OncoTree
- READ
- DOID
- 1996
- UMLS CUI
- C0149978
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Clinical trials
187 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (32)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04104139 | TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer | completed | Phase 1 | 19 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06908031 | SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer(CRIT) | completed | Phase 2 | 49 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Aug 4, 2026 |
| clinicaltrials |
| NCT04130854 | INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer | completed | Phase 2 | 58 | University of Texas Southwestern Medical CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03365882 | S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 240 | SWOG Cancer Research NetworkNETWORK | 2 | Feb 10, 2026 | clinicaltrials |
| NCT04109924 | TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study | completed | Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04362839 | Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer | completed | Phase 1 | 39 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05746195 | Optimization of Adaptive Text Messages for Cancer Survivors (OATS II) | completed | N/A | 46 | University of California, San FranciscoOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT02314182 | GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis(GRECCAR8) | completed | Phase 3 | 5 | Hospices Civils de LyonOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT02921256 | Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer | completed | Phase 2 | 363 | National Cancer Institute (NCI)NIH | 2 | Dec 4, 2025 | clinicaltrials |
| NCT02368886 | Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 2 | 123 | Academic and Community Cancer Research UnitedOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT04554836 | MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab | completed | Phase 2 | 6 | TheraOpOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT04441580 | Assessing the Additional Neoplasia Yield of Computer-aided Colonoscopy in a Screening Setting(GENIAL-CO) | completed | N/A | 900 | Fondazione Poliambulanza Istituto OspedalieroOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT01652196 | Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer | completed | Phase 2 | 56 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT01814501 | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | completed | Phase 2 | 16 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT06108596 | Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail(PICS) | completed | Phase 2 | 33 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 21, 2025 | clinicaltrials |
| NCT03436563 | M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability | completed | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT05130060 | A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer | completed | Phase 1 | 15 | Mayo ClinicOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT02132858 | Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation | completed | — | 43 | Fox Chase Cancer CenterOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT02232152 | CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery | completed | Phase 1 | 19 | Wake Forest University Health SciencesOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05872334 | The Safety and Feasibility of MONOFIX on Fascial Closure of Mid-line Wound After Minimally Invasive Colorectal Cancer Surgery | completed | N/A | 120 | Samsung Medical CenterOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT02890758 | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | completed | Phase 1 | 14 | Brenda Cooper, MDOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT03871959 | Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma(CATRIPCA) | completed | Phase 1 | 54 | Centre Leon BerardOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT03871790 | Peptide-based Immunization for Colon- and and Pancreas-carcinoma(PICOP-GLOBAL) | completed | — | 50 | CENTOGENE GmbH RostockINDUSTRY | 1 | Feb 10, 2023 | clinicaltrials |
| NCT03297710 | TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery | completed | Phase 1 | 7 | Mayo ClinicOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT02935309 | Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma | completed | Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT02270606 | Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer | completed | Phase 1 | 14 | Virginia Commonwealth UniversityOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT02393755 | Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT02641691 | Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum(NORMAL-R) | completed | Phase 2 | 20 | Washington University School of MedicineOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT01634685 | A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma | completed | Phase 1 | 15 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT01643499 | Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies | completed | Phase 1 | 79 | University of ChicagoOTHER | 1 | May 8, 2020 | clinicaltrials |
| NCT04349384 | Audit of Surgery for Colorectal Cancer(AuditCR) | completed | — | 136 | Institut National d'Oncologie, MoroccoOTHER_GOV | 1 | Apr 16, 2020 | clinicaltrials |
| NCT01674309 | First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis | completed | Phase 2 | 65 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT01802320 | Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 20, 2019 | clinicaltrials |
| NCT03899870 | Factors Predicting Recurrence in Rectal Cancer After Surgery | completed | — | 188 | ammar houssemOTHER | 0 | Apr 2, 2019 | clinicaltrials |
| NCT00321685 | Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Mar 27, 2019 | clinicaltrials |
| NCT01923337 | Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer | completed | Phase 1 | 17 | University of California, DavisOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT01282502 | Midostaurin (PKC412) for Locally Advanced Rectal Cancer | completed | Phase 1 | 19 | Massachusetts General HospitalOTHER | 1 | Dec 12, 2018 | clinicaltrials |
| NCT00068692 | Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer | completed | Phase 3 | 225 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2018 | clinicaltrials |
| NCT02017509 | Immunoscore in Rectal Cancer | completed | — | 3 | Providence Health & ServicesOTHER | 1 | Aug 29, 2018 | clinicaltrials |
| NCT01340755 | Laparoscopy-Assisted Transanal Endoscopy Rectosigmoid Resection for Rectal Cancer | completed | N/A | 5 | Massachusetts General HospitalOTHER | 1 | Sep 6, 2017 | clinicaltrials |
| NCT00307736 | Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer | completed | Phase 1 / Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01726296 | Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care | completed | N/A | 1,440 | Fox Chase Cancer CenterOTHER | 1 | Apr 6, 2017 | clinicaltrials |
| NCT01703910 | Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic | completed | Phase 2 | 29 | Centro Nacional de Investigaciones Oncologicas CARLOS IIIOTHER | 1 | Oct 9, 2015 | clinicaltrials |
| NCT00397384 | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | completed | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT00100841 | Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer | completed | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2015 | clinicaltrials |
| NCT01294826 | Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | completed | Phase 1 | 20 | Swedish Medical CenterOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01497457 | Interest of Saline MR Peritoneography for Pre-operative Assessment of Rectal Cancer | completed | N/A | 17 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | May 20, 2015 | clinicaltrials |
| NCT00032110 | Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00551421 | Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Mar 31, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Aug 6, 2026source: clinicaltrials